Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 10/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351338 | 0.78 | ALOX15 (0.59) | NPSR1 | |
| SCHEMBL4341987 | 0.77 | EGFR (0.46) | TRPV1ABCC1ALDH1A1NPSR1UBE2M | |
| SCHEMBL4351495 | 0.76 | ABCC1 (0.39) | TRPV1ABCC1ALDH1A1NPSR1TDP1 | |
| SCHEMBL4354016 | 0.75 | EGFR (0.48) | TRPV1ABCC1ALDH1A1NPSR1 | |
| SCHEMBL4341545 | 0.74 | TDP1 (0.44) | TRPV1ABCC1ALDH1A1NPSR1TDP1 | |
| SCHEMBL4342070 | 0.74 | EGFR (0.43) | TRPV1ABCC1ALDH1A1NPSR1TDP1 | |
| SCHEMBL4355633 | 0.74 | PDK1 (0.43) | TRPV1PDK1CXCR1ABCC1UBE2M | |
| SCHEMBL4345339 | 0.73 | ALDH1A1 (0.49) | MTORALDH1A1NPSR1TDP1UBE2M | |
| SCHEMBL4349798 | 0.73 | ALDH1A1 (0.46) | ALDH1A1NPSR1TDP1UBE2MDCUN1D1 | |
| SCHEMBL4343719 | 0.73 | ACHE (0.47) | MTORALDH1A1NPSR1TDP1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | TRPV1 2320/4885PDK1 517/4885CXCR1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.